These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31612423)

  • 1. High rate of acute kidney injury in patients with chronic kidney disease and hepatitis C virus genotype 4 treated with direct-acting antiviral agents.
    Elmowafy AY; El Maghrabi HM; Mashaly ME; Eldahshan KF; Rostaing L; Bakr MA
    Int Urol Nephrol; 2019 Dec; 51(12):2243-2254. PubMed ID: 31612423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of anemia on the efficacy and safety of treating chronic hepatitis C infection with direct-acting antivirals in patients with chronic kidney disease.
    Elmowafy AY; Abbas MH; Denewar AA; Mashaly ME; Shiha G; El Wasif SM; Rostaing L; Bakr MA
    Int Urol Nephrol; 2021 Apr; 53(4):749-761. PubMed ID: 33111161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
    Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
    Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience.
    Muñoz-Gómez R; Rincón D; Ahumada A; Hernández E; Devesa MJ; Izquierdo S; Ortiz M; Hernández-Albujar A; Fernández-Rodríguez C; Calvo M; González R; Lozano M; Castellano G; Fernández-Vázquez I
    J Viral Hepat; 2017 Jun; 24(6):464-471. PubMed ID: 27976490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function.
    Shin HP; Park JA; Burman B; Kozarek RA; Siddique A
    Clin Mol Hepatol; 2017 Dec; 23(4):316-322. PubMed ID: 28827512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients.
    Maghrabi HME; Elmowafy AY; Refaie AF; Elbasiony MA; Shiha GE; Rostaing L; Bakr MA
    Int Urol Nephrol; 2019 Dec; 51(12):2295-2304. PubMed ID: 31531807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute interstitial nephritis following treatment with direct-acting antiviral agents in hepatitis C virus-infected patients: A case series.
    Duque JC; Dejman A; Venkat V; Hernandez M; Roth D; Ladino MA
    Clin Nephrol; 2021 Jan; 95(1):22-27. PubMed ID: 32909545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy.
    Martínez-Campreciós J; Riveiro-Barciela M; Muñoz-Gómez R; Londoño MC; Roget M; Serra MÁ; Escudero-García D; Purchades L; Rodríguez M; Losa-García JE; Gutiérrez ML; Carmona I; García-Samaniego J; Morano L; Martín-Granizo I; Montero-Alonso M; Prieto M; Delgado M; Ramos N; Azancot MA; Rodríguez-Frías F; Buti M
    Gastroenterol Hepatol; 2023 Oct; 46(8):594-602. PubMed ID: 36584754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.
    Li T; Qu Y; Guo Y; Wang Y; Wang L
    Liver Int; 2017 Jul; 37(7):974-981. PubMed ID: 27943605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease.
    Taneja S; Duseja A; De A; Mehta M; Ramachandran R; Kumar V; Kohli HS; Gupta KL; Dhiman RK; Chawla Y
    Dig Dis Sci; 2018 May; 63(5):1334-1340. PubMed ID: 29484572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
    Goel A; Bhargava R; Rai P; Aggarwal R
    Indian J Gastroenterol; 2017 May; 36(3):227-234. PubMed ID: 28656492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease.
    Ryu JE; Song MJ; Kim SH; Kwon JH; Yoo SH; Nam SW; Nam HC; Kim HY; Kim CW; Yang H; Bae SH; Song DS; Chang UI; Yang JM; Lee SW; Lee HL; Lee SK; Sung PS; Jang JW; Choi JY; Yoon SK
    Korean J Intern Med; 2022 Sep; 37(5):958-968. PubMed ID: 35981893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HCV treatment initiation in persons with chronic kidney disease in the directly acting antiviral agents era: Results from ERCHIVES.
    Butt AA; Ren Y; Puenpatom A; Arduino JM; Kumar R; Abou-Samra AB
    Liver Int; 2018 Aug; 38(8):1411-1417. PubMed ID: 29271562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection.
    Xue Y; Zhang LX; Wang L; Li T; Qu YD; Liu F
    World J Gastroenterol; 2017 Aug; 23(32):5969-5976. PubMed ID: 28932089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection.
    Crespo J; Calleja JL; Fernández I; Sacristan B; Ruiz-Antorán B; Ampuero J; Hernández-Conde M; García-Samaniego J; Gea F; Buti M; Cabezas J; Lens S; Morillas RM; Salcines JR; Pascasio JM; Turnes J; Sáez-Royuela F; Arenas J; Rincón D; Prieto M; Jorquera F; Sanchez Ruano JJ; Navascués CA; Molina E; Moya AG; Moreno-Planas JM;
    Clin Gastroenterol Hepatol; 2017 Jun; 15(6):945-949.e1. PubMed ID: 28238958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, efficacy and cost of two direct-acting antiviral regimens: A comparative study in chronic hepatitis C Egyptian patients.
    Ibrahim Mohammed Ebid AH; Ashraf Ahmed O; Hassan Agwa S; Mohamed Abdel-Motaleb S; Mohamed Elsawy A; Hagag RS
    J Clin Pharm Ther; 2020 Jun; 45(3):539-546. PubMed ID: 31889322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD.
    Sise ME; Backman E; Ortiz GA; Hundemer GL; Ufere NN; Chute DF; Brancale J; Xu D; Wisocky J; Lin MV; Kim AY; Thadhani R; Chung RT
    Clin J Am Soc Nephrol; 2017 Oct; 12(10):1615-1623. PubMed ID: 28882857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct-acting antivirals for hepatitis C virus in patients on maintenance dialysis.
    Fabrizi F; Donato FM; Messa P
    Int J Artif Organs; 2017 Oct; 40(10):531-541. PubMed ID: 28708211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).
    Wehmeyer MH; Ingiliz P; Christensen S; Hueppe D; Lutz T; Simon KG; Schewe K; Boesecke C; Baumgarten A; Busch H; Rockstroh J; Schmutz G; Kimhofer T; Berger F; Mauss S; Schulze Zur Wiesch J
    J Med Virol; 2018 Feb; 90(2):304-312. PubMed ID: 28710853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
    Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
    J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.